BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 35508972)

  • 1. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.
    Song J; Yang R; Wei R; Du Y; He P; Liu X
    Mol Med; 2022 May; 28(1):47. PubMed ID: 35508972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of CCL5 on the immune cells infiltration and the prognosis of patients with kidney renal clear cell carcinoma.
    Bai S; Wu Y; Yan Y; Kang H; Zhang J; Ma W; Gao Y; Hui B; Li R; Zhang X; Ren J
    Int J Med Sci; 2020; 17(18):2917-2925. PubMed ID: 33173412
    [No Abstract]   [Full Text] [Related]  

  • 3. Differential Expression of the
    Hu J; Xu J; Feng X; Li Y; Hua F; Xu G
    Front Cell Dev Biol; 2021; 9():700661. PubMed ID: 34631699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
    Gao ZW; Yang L; Liu C; Wang X; Guo WT; Zhang HZ; Dong K
    Front Immunol; 2022; 13():903461. PubMed ID: 35663977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer.
    Shen Y; Lin H; Chen K; Ge W; Xia D; Wu Y; Lu W
    J Ovarian Res; 2022 Apr; 15(1):48. PubMed ID: 35477477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pancancer analysis of the carcinogenic role of receptor-interacting serine/threonine protein kinase-2 (RIPK2) in human tumours.
    Zhang H; Ma Y; Zhang Q; Liu R; Luo H; Wang X
    BMC Med Genomics; 2022 Apr; 15(1):97. PubMed ID: 35473583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value and immunological role of cathepsin S gene in pan‑cancer.
    Liang S; Dang B; Chen S; Mi H
    Oncol Lett; 2024 Jan; 27(1):41. PubMed ID: 38108072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GRAMD1A Is a Biomarker of Kidney Renal Clear Cell Carcinoma and Is Associated with Immune Infiltration in the Tumour Microenvironment.
    Liu Y; Fu S; Zhang Z; Wang S; Cheng X; Li Z; Ding Y; Sun T; Ma M
    Dis Markers; 2022; 2022():5939021. PubMed ID: 35860689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLC11A1 promotes kidney renal clear cell carcinoma (KIRC) progression by remodeling the tumor microenvironment.
    Wu D; Zhou Y; Shi X; Yi X; Sheng Z; Fan L; Ge J; Cheng W; Zhou W; He H; Fu D
    Toxicol Appl Pharmacol; 2024 Jun; 487():116975. PubMed ID: 38762191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis.
    Chen S; Huang M; Zhang L; Huang Q; Wang Y; Liang Y
    Comput Struct Biotechnol J; 2024 Dec; 23():369-383. PubMed ID: 38226313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PMEL as a Prognostic Biomarker and Negatively Associated With Immune Infiltration in Skin Cutaneous Melanoma (SKCM).
    Zhang S; Chen K; Liu H; Jing C; Zhang X; Qu C; Yu S
    J Immunother; 2021 Jul-Aug 01; 44(6):214-223. PubMed ID: 34028390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
    Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
    Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis.
    Ye Y; Jiang H; Wu Y; Wang G; Huang Y; Sun W; Zhang M
    Front Mol Biosci; 2022; 9():1001225. PubMed ID: 36213111
    [No Abstract]   [Full Text] [Related]  

  • 15. Lower Expression of GBP2 Associated With Less Immune Cell Infiltration and Poor Prognosis in Skin Cutaneous Melanoma (SKCM).
    Zhang S; Chen K; Zhao Z; Zhang X; Xu L; Liu T; Yu S
    J Immunother; 2022 Jul-Aug 01; 45(6):274-283. PubMed ID: 35543550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
    Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
    Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity.
    Wu Y; Lin Z; Tang X; Tong Z; Ji Y; Xu Y; Zhou Z; Yang J; Li Z; Liu T
    Front Immunol; 2023; 14():1182030. PubMed ID: 37388742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
    Zhang G; Chen X; Fang J; Tai P; Chen A; Cao K
    Front Immunol; 2022; 13():954440. PubMed ID: 36059510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response.
    Zheng H; Wang M; Zhang S; Hu D; Yang Q; Chen M; Zhang X; Zhang Y; Dai J; Liou YC
    Int J Biol Sci; 2023; 19(14):4689-4708. PubMed ID: 37781040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative analysis of LAG3 immune signature and identification of a LAG3-related genes prognostic signature in kidney renal clear cell carcinoma.
    Li J; Liu C; Su H; Dong H; Wang Z; Wang Y; Zhao P; Zhang C; Zhao Y; Ma X
    Aging (Albany NY); 2024 Jan; 16(3):2161-2180. PubMed ID: 38277212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.